Worldwide Health Economics and Outcomes Research Unit, Bristol Myers Squibb, Princeton, New Jersey, USA.
Offshore Delivery, Mu Sigma, Bengaluru, India.
Am J Gastroenterol. 2024 Nov 1;119(11):2326-2330. doi: 10.14309/ajg.0000000000002901. Epub 2024 Jun 24.
To evaluate real-world healthcare resource utilization (HCRU) and costs associated with eosinophilic esophagitis (EoE) in the United States.
Retrospective case-control cohort analysis of Optum Clinformatics claims data (January 2008-September 2020) comparing unadjusted and adjusted HCRU (visits per 1,000 patients per month) and all-cause costs (per patient per month).
Patients with EoE incurred significantly higher monthly HCRU (adjusted Δ [95% confidence interval]: inpatient visits, 2.8 [0.1-4.0]; emergency department visits, 14.7 [4.3-32.1]; outpatient visits, 388.8 [362.1-418.0]); and costs ($581 [$421-$600]) vs matched controls (all P < 0.001).
EoE imposes substantial economic burden. More effective and targeted treatments that improve outcomes for patients are needed.
评估美国嗜酸性食管炎（EoE）的实际医疗资源利用（HCRU）和成本。
利用 Optum Clinformatics 索赔数据（2008 年 1 月至 2020 年 9 月）进行回顾性病例对照队列分析，比较未经调整和调整后的 HCRU（每月每千名患者就诊次数）和全因成本（每名患者每月）。
EoE 患者的每月 HCRU 明显更高（调整后Δ[95%置信区间]：住院就诊次数 2.8[0.1-4.0]；急诊就诊次数 14.7[4.3-32.1]；门诊就诊次数 388.8[362.1-418.0]）和成本（581 美元[421-600 美元]）与匹配对照组相比差异均有统计学意义（均 P<0.001）。
EoE 造成了巨大的经济负担。需要更有效和有针对性的治疗方法，以改善患者的预后。
